The effect of L-Lysine on biomarkers involved in colorectal cancer

The assessment of L-Lysine effect, as complementary treatment of chemical therapy, on biomarkers involved in patients with colorectal cancer and complications of chemical therapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013010612020N1

Enrollment

Registered

2013-03-13

Start date

2013-03-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Colonl cancer. Condition 2: Rectum cancer. Malignant neoplasm of colon Malignant neoplasm of rectum

Interventions

Intervention 1: L-Lisyne powder 1.5g twice per day in combination with drugs of chemical therapy for patients in treatment group. The duration of treatment with L-lysin is 3 month. Intervention 2: In

Treatment - Drugs

L-Lisyne powder 1.5g twice per day in combination with drugs of chemical therapy for patients in treatment group. The duration of treatment with L-lysin is 3 month.

In control group : placebo is powder as the same shape and color as L-lysine in combination with chemotherapy drugs ,twice a day foe 3 month.

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- Age between 20 to 70 years; 2- The existence of colorectal cancer - Duke B; 3- The operation of colon after colorectal cancer; 4- The first time achieving chemical therapy after colorectal cancer surgery. Exclusion criteria: 1- No desire to continue the contribution in investigation during the study; 2- side effects of therapy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
ERCC1(Excision repair cross-complementing rodent repair deficiency, complementation group 1). Timepoint: Baseline and 3 monhts following the end of treatment. Method of measurement: ELISA kit.;VEGF(Vascular endothelial growth facto). Timepoint: Baseline and 3 monhts following the end of treatment. Method of measurement: ELISA kit.;DPD(Dihydropyrimidine dehydrogenase deficiency. Timepoint: Baseline and 3 monhts following the end of treatment. Method of measurement: ELISA kit.;TS(Thymidylate synthase). Timepoint: Baseline and 3 monhts following the end of treatment. Method of measurement: ELISA kit.;CEA-Carcino Embryonic Antigen. Timepoint: Baseline and 3 monhts following the end of treatment. Method of measurement: ELISA kit.	—

Measure

Time frame

ERCC1(Excision repair cross-complementing rodent repair deficiency, complementation group 1). Timepoint: Baseline and 3 monhts following the end of treatment. Method of measurement: ELISA kit.;VEGF(Vascular endothelial growth facto). Timepoint: Baseline and 3 monhts following the end of treatment. Method of measurement: ELISA kit.;DPD(Dihydropyrimidine dehydrogenase deficiency. Timepoint: Baseline and 3 monhts following the end of treatment. Method of measurement: ELISA kit.;TS(Thymidylate synthase). Timepoint: Baseline and 3 monhts following the end of treatment. Method of measurement: ELISA kit.;CEA-Carcino Embryonic Antigen. Timepoint: Baseline and 3 monhts following the end of treatment. Method of measurement: ELISA kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHajar Nikbakht

Colorectal Resaerch Center, Rasoulakaram Hospital,Tehran University of Medical Sciences

hajarnik@yahoo.com+98 21 6435 2358

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026